BRAF Mutation in Colorectal Cancer: An Enigmatic Target

被引：9
作者：
Eng, Cathy [1 ]
机构：
[1] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 04期
关键词：
FOLFIRI PLUS BEVACIZUMAB; 1ST-LINE TREATMENT; OPEN-LABEL; CETUXIMAB; FLUOROURACIL; IRINOTECAN; LEUCOVORIN; INHIBITION; SURVIVAL; MULTICENTER;
D O I：
10.1200/JCO.20.03043
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：259 / +
页数：4
相关论文
共 29 条
  • [1] [Anonymous], 2020, FDA APPROVES ENCORAF
  • [2] [Anonymous], 2018, FDA approves dabrafenib plus trametinib for anaplastic thyroid cancer with BRAF V600E mutation
  • [3] [Anonymous], 2018, FDA APPROVES ENCORAF
  • [4] BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression
    Barras, David
    Missiaglia, Edoardo
    Wirapati, Pratyaksha
    Sieber, Oliver M.
    Jorissen, Robert N.
    Love, Chris
    Molloy, Peter L.
    Jones, Ian T.
    McLaughlin, Stephen
    Gibbs, Peter
    Guinney, Justin
    Simon, Iris M.
    Roth, Arnaud D.
    Bosman, Fred T.
    Tejpar, Sabine
    Delorenzi, Mauro
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (01) : 104 - 115
  • [5] Barras David, 2015, Biomark Cancer, V7, P9, DOI 10.4137/BIC.S25248
  • [6] Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients
    Corcoran, R.
    Giannakis, M.
    Allen, J.
    Chen, J.
    Pelka, K.
    Chao, S.
    Meyerhardt, J.
    Enzinger, A.
    Enzinger, P.
    McCleary, N.
    Yugelun, M.
    Abrams, T.
    Kanter, K.
    Van Seventer, E.
    Bradford, W.
    Fetter, I.
    Siravegna, G.
    Tian, J.
    Clark, J.
    Ryan, D.
    Hacohen, N.
    Parikh, A.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S226 - S227
  • [7] Combined BRAF, EGFR, and MEK Inhibition in Patients with &ITBRAF&ITV600E-Mutant Colorectal Cancer
    Corcoran, Ryan B.
    Andre, Thierry
    Atreya, Chloe E.
    Schellens, Jan H. M.
    Yoshino, Takayuki
    Bendell, Johanna C.
    Hollebecque, Antoine
    McRee, Autumn J.
    Siena, Salvatore
    Middleton, Gary
    Muro, Kei
    Gordon, Michael S.
    Tabernero, Josep
    Yaeger, Rona
    O'Dwyer, Peter J.
    Humblet, Yves
    De Vos, Filip
    Jung, A. Scott
    Brase, Jan C.
    Jaeger, Savina
    Bettinger, Severine
    Mookerjee, Bijoyesh
    Rangwala, Fatima
    Van Cutsem, Eric
    [J]. CANCER DISCOVERY, 2018, 8 (04) : 428 - 443
  • [8] EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
    Corcoran, Ryan B.
    Ebi, Hiromichi
    Turke, Alexa B.
    Coffee, Erin M.
    Nishino, Michiya
    Cogdill, Alexandria P.
    Brown, Ronald D.
    Della Pelle, Patricia
    Dias-Santagata, Dora
    Hung, Kenneth E.
    Flaherty, Keith T.
    Piris, Adriano
    Wargo, Jennifer A.
    Settleman, Jeffrey
    Mino-Kenudson, Mari
    Engelman, Jeffrey A.
    [J]. CANCER DISCOVERY, 2012, 2 (03) : 227 - 235
  • [9] Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer
    Cremolini, Chiara
    Antoniotti, Carlotta
    Stein, Alexander
    Bendell, Johanna
    Gruenberger, Thomas
    Rossini, Daniele
    Masi, Gianluca
    Ongaro, Elena
    Hurwitz, Herbert
    Falcone, Alfredo
    Schmoll, Hans-Joachim
    Di Maio, Massimo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (28) : 3314 - 3324
  • [10] FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
    Cremolini, Chiara
    Loupakis, Fotios
    Antoniotti, Carlotta
    Lupi, Cristiana
    Sensi, Elisa
    Lonardi, Sara
    Mezi, Silvia
    Tomasello, Gianluca
    Ronzoni, Monica
    Zaniboni, Alberto
    Tonini, Giuseppe
    Carlomagno, Chiara
    Allegrini, Giacomo
    Chiara, Silvana
    D'Amico, Mauro
    Granetto, Cristina
    Cazzaniga, Marina
    Boni, Luca
    Fontanini, Gabriella
    Falcone, Alfredo
    [J]. LANCET ONCOLOGY, 2015, 16 (13) : 1306 - 1315
123